NEW YORK (GenomeWeb) — Bay Area startup Toma Biosciences emerged from stealth mode this month with a new cancer assay designed to provide physicians with information to help them personalize and optimize treatments for cancer patients.
Bio-Rad Laboratories this week announced an expansion of its PrimePCR probe assays for Droplet Digital PCR, adding 56 assays for mutation detection and 109 assays for copy number variation analysis to the company's existing catalog for the QX100 and QX200 Droplet Digital PCR systems.
Researchers from several European institutions have used a clinical trial of children with stage IV neuroblastoma to test prospectively whether varying levels of several mRNA markers could stratify patients according to their outcomes.
A research team from Jena University Hospital at the Friedrich Schiller University in Germany has developed a method it calls digital direct RT-PCR (DD-RT-PCR) to quantify circulating tumor cells in cervical cancer by detecting HPV-oncogene transcripts.
Using a microfluidic device called SlipChip, a cell phone camera, and cloud computing, a California Institute of Technology team has shown the superiority of digital over real-time isothermal PCR under perturbed experimental conditions.